Invention Grant
- Patent Title: Cancer treatment utilizing SP-141 to bind with MDM2 and act as an inhibitor of MDM2 expression
-
Application No.: US15513882Application Date: 2015-09-25
-
Publication No.: US10472355B2Publication Date: 2019-11-12
- Inventor: Ruiwen Zhang , Wei Wang
- Applicant: Texas Tech University System
- Applicant Address: US TX Lubbock
- Assignee: Texas Tech University System
- Current Assignee: Texas Tech University System
- Current Assignee Address: US TX Lubbock
- Agent Kevin L. Soules; Kermit D. Lopez; Luis M. Ortiz
- International Application: PCT/US2015/052216 WO 20150925
- International Announcement: WO2016/049453 WO 20160331
- Main IPC: C07D471/04
- IPC: C07D471/04
Abstract:
An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.
Public/Granted literature
- US20170283413A1 CANCER TREATMENT UTILIZING SP-141 TO BIND WITH MDM2 AND ACT AS AN INHIBITOR OF MDM2 EXPRESSION Public/Granted day:2017-10-05
Information query
